Glenmark Pharmaceuticals’ subsidiary — Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Metformin Hydrochloride Extended‐Release Tablets USP, 500 mg and 1000 mg, the generic version of Glumetza Extended‐Release Tablets, 500 mg and 1000 mg, of Salix Pharmaceuticals Inc.
According to IQVIA sales data for the 12‐month period ending September 2019, the Glumetza Tablets, 500 mg and 1000 mg market achieved annual sales of approximately $226.7 million.
Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).